Haemonetics Corporation Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31)
Haemonetics Corporation (HAE) reported Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) of $16.00 million for the 9-month period ending 2013-12-28, per its 10-Q filed 2014-01-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostCostIncurredToDate · last filed 2014-01-30
- 2013-12-28: Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) 9 month $16.00M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date (Deprecated 2014-01-31) 9 month |
|---|---|
| 2013-12-28 | $16.00M 10-Q · filed 2014-01-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| PULSE BIOSCIENCES, INC. (PLSE) | United States | $3.696B | -24.47 |
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |